Private equity firms Nordic Capital and Permira announced a DKK 19 billion (USD 2.8 billion) acquisition of Bavarian Nordic on 28 July, offering DKK 233 per share—a 21% premium to its 23 July closing price. The deal for the Copenhagen-based vaccine specialist, known for its monkeypox vaccine Imvamune and Ebola vaccine Mvabea, is expected to close in Q4 2025 pending regulatory approvals.

The acquisition will support Bavarian Nordic's expansion into global vaccine markets, including its recently launched chikungunya vaccine Vimkunya. Nordic Capital highlighted Bavarian's successful transition from contract manufacturing to a commercial-stage company with USD 1.2 billion in 2024 revenue. Post-acquisition plans include delisting Bavarian's shares and pursuing strategic mergers to diversify its infectious disease portfolio.

According to PharmCube's NextBiopharm® database, Bavarian Nordic has 28 programs in its pipeline. Click here to request a free trial for NextBiopharm®.